CTI BioPharma Corp. announced that Laurent Fischer, M.D. has been appointed its new Chairman of the Board and the promotion of David H. Kirske to Chief Financial Officer and Bruce J. Seeley to Chief Operating Officer of the company. Fischer has been a director at the company since July, 2017.

Dr. Fischer is currently Senior Vice President, Head of the Liver Therapeutic Area at Allergan following the acquisition of Tobira Therapeutics. Dr. Fischer has served as a Senior Advisor on the Frazier Healthcare Partners' Life Sciences team since March 2017. He was previously chairman and CEO of Jennerex Inc. David H. Kirske joined the company earlier in 2017 and served as the Principal Financial and Accounting Officer prior to being appointed Chief Financial Officer.

Mr. Kirske's financial management experience includes overseeing finance, accounting, operations, and capitalization, in both debt and equity. Prior to joining CTI BioPharma, he was an independent CFO consultant since January 2013. Bruce J. Seeley joined the company in 2015 and served as the Chief Commercial and Adminstrative Officer and Secretary prior to being appointed Chief Operating Officer.

Mr. Seeley has more than 25 years of global commercial experience and a proven track record of successfully launching products in various markets and regulatory environments. Most recently, Mr. Seeley was Senior Vice President and General Manager of Diagnostics at NanoString Technologies Inc.